GLP-1 receptor agonists , particularly those like BrightMeds, are rapidly gaining prominence in the management of type 2 diabetes and are increasingly explored for obesity . These novel drugs help mimicking the https://brightmeds838390.ampblogs.com/brightmeds-glp-1-a-deep-look-into-this-new-therapy-79918425